Sepiapterin API is a specialized pharmaceutical active ingredient associated with the tetrahydrobiopterin (BH4) metabolic pathway and phenylalanine hydroxylase (PAH) activity. Chemically, sepiapterin is identified by CAS Number 17094-01-8, with the molecular formula C₉H₁₁N₅O₃ and a molecular weight of 237.22 g/mol. It is a chiral small-molecule compound and is recognized as a precursor involved in the biosynthesis and salvage of tetrahydrobiopterin.
The pharmaceutical importance of Sepiapterin has increased with its development for the treatment of phenylketonuria (PKU). Sepiapterin works by increasing the availability of tetrahydrobiopterin, an important cofactor required for phenylalanine hydroxylase. In patients whose PKU is responsive to sepiapterin, enhanced PAH activity can help improve the metabolism of phenylalanine and support the reduction of elevated phenylalanine concentrations.
Tetrahydrobiopterin is an essential cofactor involved in several enzymatic reactions within human metabolism. One of its important roles is supporting phenylalanine hydroxylase, the enzyme responsible for converting phenylalanine into tyrosine.
In phenylketonuria, impaired PAH activity can result in the accumulation of phenylalanine in the blood. Sepiapterin provides a metabolic precursor that can contribute to intracellular BH4 availability. This mechanism makes Sepiapterin API particularly relevant to pharmaceutical research and the development of treatments for BH4-responsive or sepiapterin-responsive metabolic disorders.
The mechanism of action also distinguishes sepiapterin from conventional pharmaceutical compounds that directly inhibit or activate a target receptor. Its therapeutic effect is closely connected with cellular metabolism and cofactor availability.
The principal pharmaceutical application of sepiapterin is associated with phenylketonuria and hyperphenylalaninemia. In July 2025, the U.S. FDA approved sepiapterin for the treatment of hyperphenylalaninemia in adults and pediatric patients one month of age and older with sepiapterin-responsive PKU, together with a phenylalanine-restricted diet.
This regulatory development has increased interest in Sepiapterin Pharmaceutical API for pharmaceutical development, analytical research and commercial drug manufacturing.
Beyond its established application in PKU, sepiapterin remains an important compound for research involving pterin metabolism, phenylalanine metabolism, PAH activity and related metabolic pathways.
Sepiapterin is reported as a yellow to orange powder. It has a molecular weight of 237.22 g/mol and contains one chiral center. Its physicochemical characteristics are important considerations during pharmaceutical processing and quality control.
The compound has reported pKa values of approximately 1.27 and 9.95, while FDA pharmaceutical development information reports a melting point of approximately 223.3°C. Sepiapterin is described as slightly soluble in water and several common alcohol solvents. Its aqueous solubility is approximately 1.4 mg/mL under the conditions reported by FDA.
Sepiapterin is also described as moderately hygroscopic. Consequently, moisture exposure can be an important consideration during API handling, packaging and storage.
High-quality Sepiapterin API requires comprehensive analytical characterization to establish identity, assay, purity and consistency between manufacturing batches. Analytical testing can include infrared identification, HPLC assay, related-substance analysis, chiral purity testing, water determination and residue-on-ignition testing.
Because sepiapterin is a chiral compound, control of its stereochemical quality is an important part of pharmaceutical API characterization. Chromatographic methods can be used to evaluate chiral purity and related substances.
Residual solvents and elemental impurities should also be controlled according to applicable pharmaceutical quality requirements. Solid-state characterization may be relevant because different crystalline forms of sepiapterin have been reported.
A Sepiapterin API Manufacturer in India should maintain a controlled manufacturing process supported by appropriate analytical procedures, quality systems and batch traceability. Pharmaceutical-grade production requires attention to raw-material quality, process controls, impurity formation, stereochemical consistency and moisture management.
The API manufacturing process should be supported by appropriate documentation such as a Certificate of Analysis (CoA), product specification, analytical test methods, impurity profile and stability information, depending on the intended pharmaceutical application and regulatory requirements.
For commercial pharmaceutical manufacturing, consistent batch quality is particularly important because sepiapterin is a specialized active ingredient with defined physicochemical and analytical characteristics.
Appropriate packaging is essential for maintaining the quality of sepiapterin during transportation and storage. Since the compound has hygroscopic characteristics, moisture-protective packaging should be considered.
Pharmaceutical active material can be packaged using suitable sealed primary packaging with an effective moisture barrier. The EMA assessment documentation describes packaging involving LDPE bags, an aluminium foil barrier and an HDPE drum, with nitrogen protection.
Storage conditions should follow the validated stability data and approved product/API specification. Exposure to excessive humidity and unsuitable environmental conditions should be minimized.
The growing pharmaceutical interest in sepiapterin creates opportunities for its use in API development, formulation research, analytical development and commercial pharmaceutical manufacturing. Its relationship with the BH4 pathway and PAH activity makes it a distinctive compound within the metabolic-disease therapeutic area.
For pharmaceutical companies evaluating Sepiapterin Bulk API, important considerations include chemical identity, stereochemical purity, chromatographic purity, water content, residual solvents, solid-state characteristics, packaging and regulatory documentation.
A dependable Sepiapterin API Manufacturer in India can therefore support pharmaceutical development by providing consistent material quality, analytical documentation and appropriate quality-control information for each batch.
Sepiapterin is an increasingly important pharmaceutical compound because of its application in sepiapterin-responsive PKU and its role in the BH4 metabolic pathway. Pharmaceutical-grade material should be manufactured under controlled conditions and evaluated using validated analytical procedures.
Key quality considerations include CAS 17094-01-8 identity confirmation, HPLC purity, chiral purity, moisture control, residual-solvent testing, impurity profiling and appropriate packaging.
With proper manufacturing controls and comprehensive quality documentation, Sepiapterin API can provide a reliable pharmaceutical raw material for drug development, formulation and commercial manufacturing applications.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Melting Point | 223.3°C |